Rutgers Researcher Awarded $954,000 for Work on Prostate Cancer Hormone Therapy Xtandi

Rutgers Researcher Awarded $954,000 for Work on Prostate Cancer Hormone Therapy Xtandi
The chief of urologic oncology at Rutgers Cancer Institute of New Jersey, Isaac Yi Kim, MD, PhD, MBA, has been awarded a $954,000 Prostate Cancer Research Program Idea Development Award for Established Investigators to support work on a hormone therapy, Xtandi (enzalutamide), which targets a protein that prostate cancer cells need for growth and survival.

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Herschell Atkinson says:

    I am approaching the 2 year mark on Xtandi and my PSA is starting to show an increase. 2.17 in August and an increase to 3.35 this month (December). Any thoughts, or recommendations for a next step for treatment?

Leave a Comment

Your email address will not be published. Required fields are marked *